Loading
A phase 1/2 trial of an investigational treatment in advanced solid tumours, run by CAS Lamvac Biotech Co., Ltd., now recruiting.
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors is a phase 1/2 interventional study registered as NCT04165590 by CAS Lamvac Biotech Co., Ltd., with 60 participants planned, started 2019-10-24 and due to reach its primary completion in 2024-04-30.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/